<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Efficacy of a new <z:chebi fb="1" ids="35705">immunosuppressive agent</z:chebi>, FK506, in refractory <z:hpo ids='HP_0000554'>uveitis</z:hpo> was studied in 8 patients: 5 with <z:e sem="disease" ids="C0004943" disease_type="Disease or Syndrome" abbrv="">Behcet's disease</z:e> and 3 with idiopathic <z:chebi fb="46" ids="15035">retinal</z:chebi> <z:hpo ids='HP_0002633'>vasculitis</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>The agent was given by oral administration every 12 hours </plain></SENT>
<SENT sid="2" pm="."><plain>The previous therapy with systemic <z:chebi fb="0" ids="50858">corticosteroids</z:chebi> or <z:chebi fb="1" ids="35705">immunosuppressive agents</z:chebi> including <z:chebi fb="0" ids="4031">cyclosporine</z:chebi> failed to subside <z:hpo ids='HP_0000554'>uveitis</z:hpo> in these cases </plain></SENT>
<SENT sid="3" pm="."><plain>During the observation period of 21.6 +/- 7.8 weeks (mean +/- SD) under FK506 at doses with 0.05, 0.1, 0.15 or 0.2 mg/kg/day, the visual acuity was increased in 44% of treated eyes, unchanged in 44% and decreased in 12% </plain></SENT>
<SENT sid="4" pm="."><plain>The inflammatory activity in the ocular fundus was improved in 69% and unchanged in 6% of treated eyes </plain></SENT>
<SENT sid="5" pm="."><plain>The effects of FK506 on <z:hpo ids='HP_0000554'>uveitis</z:hpo> by the criteria of improvement of visual acuity and <z:hpo ids='HP_0000554'>uveitis</z:hpo> activity was dose-dependent: 0.05 and 0.1 mg/kg/day were ineffective but 0.15 and 0.2 mg/kg/day were effective in most cases </plain></SENT>
<SENT sid="6" pm="."><plain>One patient with <z:e sem="disease" ids="C0004943" disease_type="Disease or Syndrome" abbrv="">Behcet's disease</z:e> converted from <z:chebi fb="0" ids="4031">cyclosporine</z:chebi> developed moderate <z:e sem="disease" ids="C0341697" disease_type="Disease or Syndrome" abbrv="">renal impairment</z:e> in 4 weeks under FK506 and the therapy was discontinued in 8 weeks, though the <z:hpo ids='HP_0000554'>uveitis</z:hpo> activity as well as visual acuity was markedly improved </plain></SENT>
<SENT sid="7" pm="."><plain>Other 7 cases had no side effect of FK506 </plain></SENT>
<SENT sid="8" pm="."><plain>Although the number of cases was small and observation period was short, the present clinical data indicate that FK506 is effective to treat refractory <z:hpo ids='HP_0000554'>uveitis</z:hpo> </plain></SENT>
</text></document>